Roswell Park Cancer Institute (RPCI) has considerable expertise in the development and conduct of pilot/pre-phase I, phase I and phase l/ll studies, which are the foundation for the development of novel therapeutic approaches in hematologic and solid tumor malignancies. Early Phase Clinical Research Support (EPCRS) provides resources for the short-term conduct of early phase agent or device studies developed by RPCI investigators and emanating from the CCSG research programs. The continued vitality and translational potential of CCSG Programs relies critically on this support for early phase studies, which rarely receive support through other mechanisms. With the recent recruitment of a number of new investigators to the CCSG Programs and RPCI, accrual to these studies has increased substantially, for example, from 24 (2008) to 118 (2012) for phase I investigator-initiated studies. Alex A. Adjei, MD, PhD, Associate Director for Clinical Research, oversees this CCSG component. The primary responsibilities of the clinical research coordinators in this Resource are the implementation, conduct, oversight, collection and quality control of data for phase I and pilot studies. Dr. Adjei oversees the prioritization for the use of EPCRS resources in his capacity as Associate Director for Clinical Research. The process builds on established mechanisms and structures through the Protocol Review and Monitoring System to ensure that only high priority, eligible studies receive support. In order to be eligible for support through EPCRS, the study must be led by an RPCI investigator and/or have resulted from clinical or preclinical studies performed by an RPCI investigator with an RPCI faculty member as a co-investigator. In addition, the study should not be supported by peer-reviewed funding, a co-operative agreement or other contracts. Over the last grant period, a number of studies have been initiated that were based on research findings from investigators involved in the CCSG programs. These trials either had laboratory funding but not clinical trial funding or they led to peer-reviewed funding after support by the EPPRS. Examples include phase I studies of TRC105 [Dr. Ben Seon (TM)] DAMD17031046), cixutumumab + eriofinib [Adjei (ET), R21 CAI 35595], Eriofinib chemoprevention [Dr. Mary Reid (PS), N01 CN-35157], and a vaccine study for NY-ESO expressing ovarian and fallopian tube cancers [Dr. Kunle Odunsi/Dr. ProtuI Shrikant (TH), R01CA158318].
Eariy phase clinical research is essential to translating outstanding basic science into clinical care. EPCRS provides critical support to advance the most novel science into clinical testing prior to extramural funding.
|Ciamporcero, Eric; Miles, Kiersten Marie; Adelaiye, Remi et al. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-10|
|Ma, Yingyu; Hu, Qiang; Luo, Wei et al. (2015) 1?,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol 148:166-71|
|Shen, Li; Sundstedt, Anette; Ciesielski, Michael et al. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136-48|
|Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie et al. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 14:513-22|
|Uekusa, Shota; Kawashima, Hiroyuki; Sugito, Kiminobu et al. (2014) Nr4a3, a possibile oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon. Int J Oncol 44:1669-77|
|Ambrosone, Christine B; Zirpoli, Gary; Ruszczyk, Melanie et al. (2014) Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control 25:259-65|
|Röhm, Marc; Grimm, Melissa J; D'Auria, Anthony C et al. (2014) NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect Immun 82:1766-77|
|Rohrbach, Daniel J; Muffoletto, Daniel; Huihui, Jonathan et al. (2014) Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging. Acad Radiol 21:263-70|
|Ambrosone, Christine B; Young, Allyson C; Sucheston, Lara E et al. (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5:237-48|
|O'Brien, Shalana; Golubovskaya, Vita M; Conroy, Jeffrey et al. (2014) FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget 5:7945-59|
Showing the most recent 10 out of 517 publications